Cumberland Pharmaceuticals Inc. (CPIX): Price and Financial Metrics


Cumberland Pharmaceuticals Inc. (CPIX)

Today's Latest Price: $2.99 USD

0.04 (1.36%)

Updated Oct 29 12:20pm

Add CPIX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

CPIX Stock Summary

  • CPIX has a higher market value than merely 14.78% of US stocks; more precisely, its current market capitalization is $44,658,938.
  • In terms of volatility of its share price, CPIX is more volatile than merely 24.42% of stocks we're observing.
  • Cumberland Pharmaceuticals Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 14.64%, greater than the shareholder yield of 84.83% of stocks in our set.
  • Stocks that are quantitatively similar to CPIX, based on their financial statements, market capitalization, and price volatility, are MMSI, INTT, TACT, PLPC, and NSSC.
  • Visit CPIX's SEC page to see the company's official filings. To visit the company's web site, go to www.cumberlandpharma.com.

CPIX Stock Price Chart Interactive Chart >

Price chart for CPIX

CPIX Price/Volume Stats

Current price $2.99 52-week high $5.80
Prev. close $2.95 52-week low $2.89
Day low $2.98 Volume 2,690
Day high $3.01 Avg. volume 27,204
50-day MA $3.20 Dividend yield N/A
200-day MA $3.66 Market Cap 45.27M

Cumberland Pharmaceuticals Inc. (CPIX) Company Bio


Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the hospital acute care and gastroenterology markets in the United States and internationally. The company was founded in 1999 and is based in Nashville, Tennessee.

CPIX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$2.99$1.43 -52%

Below please find a table outlining a discounted cash flow forecast for CPIX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Cumberland Pharmaceuticals Inc ranked in the 29th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Cumberland Pharmaceuticals Inc ended up being:

  • Cumberland Pharmaceuticals Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -18.66. This coverage rate is greater than that of just 6.13% of stocks we're observing for the purpose of forecasting via discounted cash flows.
  • As a business, Cumberland Pharmaceuticals Inc experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than only 0% of stocks generating free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-53%
1%-52%
2%-52%
3%-51%
4%-51%
5%-50%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as CPIX, try ILMN, JNJ, LMAT, ZTS, and HAPP.


CPIX Latest News Stream


Event/Time News Detail
Loading, please wait...

CPIX Latest Social Stream


Loading social stream, please wait...

View Full CPIX Social Stream

Latest CPIX News From Around the Web

Below are the latest news stories about Cumberland Pharmaceuticals Inc that investors may wish to consider to help them evaluate CPIX as an investment opportunity.

Newly Published Literature Supports Use Of Caldolor® For Postoperative Pain And Reduction Of Opioid Use

NASHVILLE, Tenn., Aug. 18, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the results of a new review of clinical studies evaluating Caldolor® (ibuprofen) Injection, which was published in the journal Clinical…

PR Newswire | August 18, 2020

Cumberland Pharmaceuticals Inc. 2020 Q2 - Results - Earnings Call Presentation

The following slide deck was published by Cumberland Pharmaceuticals Inc. in conjunction with their 2020 Q2 earnings call....

SA Transcripts on Seeking Alpha | August 12, 2020

Cumberland Pharmaceuticals, Inc. (CPIX) CEO A. J. Kazimi on Q2 2020 Results - Earnings Call Transcript

Cumberland Pharmaceuticals, Inc. (CPIX) Q2 2020 Earnings Conference Call August 11, 2020 04:30 PM ET Company Participants Erin Gull - IR A. J. Kazimi - CEO Marty Cearnal - Chief Commercial Officer Michael Bonner - CFO Conference Call Participants Andrew D'Silva - B. Riley FBR Presentation Operator Thanks to everyone...

SA Transcripts on Seeking Alpha | August 12, 2020

Caldolor® Demonstrates Significant Reduction Of Opioid Use In Orthopedic Trauma Patients

NASHVILLE, Tenn., July 20, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the results of a Level 1 Trauma Center study recently published in the Journal of Orthopedic Trauma. Results demonstrate Caldolor®…

PR Newswire | July 20, 2020

All You Need to Know About Cumberland (CPIX) Rating Upgrade to Buy

Cumberland (CPIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

Yahoo | June 15, 2020

Read More 'CPIX' Stories Here

CPIX Price Returns

1-mo -6.56%
3-mo -10.21%
6-mo -23.53%
1-year -44.01%
3-year -59.21%
5-year -51.77%
YTD -41.94%
2019 -14.59%
2018 -18.07%
2017 33.82%
2016 4.56%
2015 -12.04%

Continue Researching CPIX

Here are a few links from around the web to help you further your research on Cumberland Pharmaceuticals Inc's stock as an investment opportunity:

Cumberland Pharmaceuticals Inc (CPIX) Stock Price | Nasdaq
Cumberland Pharmaceuticals Inc (CPIX) Stock Quote, History and News - Yahoo Finance
Cumberland Pharmaceuticals Inc (CPIX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8276 seconds.